Inclusion Criteria:

- UICC TNM stage 0 (i.e. in situ disease), 1 or 2 breast cancer patients treated with
conservative surgery and adjuvant radiotherapy with chronic breast pain or
tenderness, with or without fibrosis, within 3 months to 3 years following completion
of radiotherapy

- Age 18 to 75 years of age

- Chronic symptoms localised to the breast treated with radiation, i.e. any one or more
of the following- pain (not attributable to infection) or tenderness with or without
associated oedema, fibrosis, necrosis or ulceration.

- Breast pain (maximum in the previous 24 hours) measurable on a Linear Analogue Scale
with a length of 3cm or greater

- Prior treatment with radiation to the affected area i.e. in tangential breast fields
or boost area

- Radiation completed at least 3 months and no longer than 3 years prior to study entry

- Informed consent

Exclusion Criteria:

- Active cellulitis in the breast

- Active malignant disease

- Any medical illness or condition judged likely by the local investigator to preclude
safe administration of protocol treatment

- Contraindication to treatment with pentoxifylline (i.e. previously exhibited
intolerance to pentoxifylline or other xanthines such as caffeine, theophylline or
theobromine; recent cerebral and/or retinal haemorrhage; ischaemic heart disease;
hypotension

- Pregnant or lactating women